Mechanisms of checkpoint inhibition-induced adverse events

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1 have transformed melanoma and NSCLC treatment.
• ICI therapy stimulates the immune system against cancer but can reduce self-tolerance, leading to immune-related adverse events (irAEs).
• irAEs manifest as autoimmune-like toxicities, varying unpredictably in onset and severity across all organ systems.

Purpose of the Study:

• To review evidence on the mechanisms underlying ICI-induced toxicity.
• To explore methods for predicting which patients are at risk of developing irAEs.
• To discuss future directions in managing and predicting ICI-related toxicities.

Main Methods:

• Literature review of published studies on ICI mechanisms and toxicity.
• Analysis of reported cases and experimental investigations into irAEs.
• Synthesis of current knowledge on predictive biomarkers and management strategies.

Main Results:

• Multiple mechanisms for irAEs have been proposed but no consensus exists.
• Current methods for predicting irAE risk are limited.
• The unpredictable nature of irAEs poses a significant clinical challenge.

Conclusions:

• Understanding ICI toxicity mechanisms is crucial for improving patient safety.
• Development of reliable predictive tools for irAEs is a key future goal.
• Further research is needed to optimize ICI therapy and mitigate its adverse effects.